|
|
Dr. Martin GleaveDr. Martin Gleave, Director at the Prostate Centre at VGH heads the PC-TRIADD (Prostate Centre's Translational Initiative for Accelerated Discovery and Development) team, contributing tremendously to the research and fight against prostate cancer, one of the leading causes of death in North American men. Dr. Gleave's major research focus involves the study of cellular and molecular mechanisms affecting progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop new and more efficient therapies that specifically target these mechanisms. PC-TRIADD aims to comprehensively and rapidly characterize progression-related changes in gene expression, and to translate this into human trials of new drugs targeting these changes. Through PC-TRIADD, Dr. Gleave has raised more than $50 million in peer-reviewed grant funding and helped create one of the world's most comprehensive prostate cancer research facilities. Dr. Gleave is also the founder & CSO of OncoGenex, a company focused on leveraging partnerships between universities and industry to facilitate translation of preclinical observations into the clinic. In addition, he is an active member of the Department of Urologic Sciences and is considered one of the best surgical educators in the country. Dr. Gleave is a skilled surgeon, talented scientist, teacher and superb critical thinker who has made significant contributions to medical science. |
